Top in cardiology: Dysmenorrhea, PCOS tied to CVD risk; more from AHA Scientific Sessions
Click Here to Manage Email Alerts
Dysmenorrhea and polycystic ovary syndrome are linked to a long-term increased risk for CVD in women, according to a presentation at the American Heart Association Scientific Sessions.
One study in the presentation identified a higher risk for ischemic heart disease among women aged younger than 50 years who have dysmenorrhea, compared with women who do not experience painful menstrual periods. In a different study, girls aged 13 to 17 years with PCOS had a higher risk for high BP than girls without PCOS.
“Finding new markers of cardiovascular risk in young women is required to improve screening and preventive measures,” Eugenia Alleva, MD, MSc, a postdoctoral research fellow at the Windreich Department of Artificial Intelligence and Human Health and the Hasso Plattner Institute for Digital Health at Mount Sinai, told Healio. “OB/GYNs are becoming increasingly involved in their patients’ long-term health beyond reproductive health.”
It was the top story in cardiology last week.
In another top story, topline data from a phase 3 trial demonstrated benefits of aficamten (Cytokinetics) among patients with obstructive hypertrophic cardiomyopathy (HCM). Compared with placebo, aficamten was associated with an increase in exercise capacity and improvements in obstructive HCM symptoms.
Read these and more top stories, including coverage from the AHA Scientific Sessions, below:
Menstrual cycle disorders tied to increasing CVD risk in young women, teens
Two common reproductive health conditions, dysmenorrhea and polycystic ovary syndrome, are associated with increasing CVD risk in women, according to research presented at the American Heart Association Scientific Sessions. Read more.
Topline data show aficamten improves outcomes for adults with obstructive HCM
Compared with placebo, aficamten was associated with increased exercise capacity and improvements in symptoms of obstructive hypertrophic cardiomyopathy, according to topline results of the phase 3 SEQUOIA-HCM trial. Read more.
Lifestyle intervention improves daily steps but not functional capacity in HFrEF
In patients with heart failure with reduced ejection fraction, a lifestyle intervention improved daily steps by 25%, but that did not translate to improvement in functional capacity, according to the results of the WATCHFUL trial. Read more.
VIDEO: Gina Lundberg, MD, FACC, discusses navigating illness of a close family member
In this Healio video exclusive, Gina Lundberg, MD, FACC, discusses the anxiety and distress a clinician might feel when a spouse, child or close family member is navigating a serious illness. Watch video.
AHA launches ‘timely’ tobacco treatment professional certification
Quitting smoking or other tobacco products can be difficult under the best circumstances. Cardiologists can help patients who want to quit, but data show more training is needed on optimal strategies and available therapies. Read more.